Literature DB >> 9718590

Characterization of the translocation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA/ecstasy) in synaptosomes: evidence for a presynaptic localization involving the serotonin transporter (SERT).

H K Kramer1, J C Poblete, E C Azmitia.   

Abstract

3, 4-methylenedioxymethamphetamine (MDMA or Ecstasy) is a substituted amphetamine whose acute and long-term effects on the serotonin system are dependent on an interaction with the 5-HT uptake transporter (SERT). Although much of the work dedicated to the study of this compound has focused on its ability to release monoamines, this drug has many important metabolic consequences on neurons and glial cells. The identification of these physiological responses will help to bridge the gap that exists in the information between the acute and neurotoxic effects of amphetamines. Substituted amphetamines have the ability to produce a long-term translocation of protein kinase C (PKC) in vivo, and this action may be crucial to the development of serotonergic neurotoxicity. Our earlier results suggested that PKC activation occurred through pre- and postsynaptic mechanisms. Because the primary site of action of these drugs is the 5-HT transporter, we now expand on our previous results and attempt to characterize MDMA's ability to translocate PKC within cortical 5-HT nerve terminals. In synaptosomes, MDMA produced a concentration-dependent increase in membrane-bound PKC (as measured by 3H-phorbol 12, 13 dibutyrate, 3H-PDBu) bindings sites. This response was abolished by cotreatment with the specific serotonin reuptake inhibitor (SSRI), fluoxetine, but not by the 5-HT2A/2C antagonist, ketanserin. In contrast, full agonists to 5-HT1A and 5-HT2 receptors did not produce significant PKC translocation. MDMA-mediated PKC translocation also requires the presence of extracellular calcium ions. Using assay conditions where extracellular calcium was absent prevented in vitro activation of PKC by MDMA. Prolonged PKC translocation has been hypothesized to contribute to the calcium-dependent neurotoxicity produced by substituted amphetamines. In addition, many physiological processes within 5-HT nerve terminals, including 5-HT reuptake and vesicular serotonin release, are susceptible to modification by PKC-dependent protein phosphorylation. Our results suggest that prolonged activation of PKC within the 5-HT nerve terminal may contribute to lasting changes in the homeostatic function of 5-HT neurons, leading to the degeneration of specific cellular elements after repeated MDMA exposure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9718590     DOI: 10.1016/S0893-133X(98)00027-X

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  6 in total

Review 1.  Protein kinase C isozymes and addiction.

Authors:  M Foster Olive; Robert O Messing
Journal:  Mol Neurobiol       Date:  2004-04       Impact factor: 5.590

2.  Analysis of transcriptional responses in the mouse dorsal striatum following acute 3,4-methylenedioxymethamphetamine (ecstasy): identification of extracellular signal-regulated kinase-controlled genes.

Authors:  J Salzmann; C Canestrelli; F Noble; C Marie-Claire
Journal:  Neuroscience       Date:  2005-11-14       Impact factor: 3.590

3.  Sigma (σ) receptor ligand, AC927 (N-phenethylpiperidine oxalate), attenuates methamphetamine-induced hyperthermia and serotonin damage in mice.

Authors:  Michael J Seminerio; Nidhi Kaushal; Jamaluddin Shaikh; Jason D Huber; Andrew Coop; Rae R Matsumoto
Journal:  Pharmacol Biochem Behav       Date:  2010-12-02       Impact factor: 3.533

4.  PKCβ Inhibitors Attenuate Amphetamine-Stimulated Dopamine Efflux.

Authors:  Alexander G Zestos; Sarah R Mikelman; Robert T Kennedy; Margaret E Gnegy
Journal:  ACS Chem Neurosci       Date:  2016-03-28       Impact factor: 4.418

Review 5.  Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.

Authors:  João Paulo Capela; Helena Carmo; Fernando Remião; Maria Lourdes Bastos; Andreas Meisel; Félix Carvalho
Journal:  Mol Neurobiol       Date:  2009-04-17       Impact factor: 5.590

6.  Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.

Authors:  Mireia Segura; Magí Farré; Simona Pichini; Ana M Peiró; Pere N Roset; Ariel Ramírez; Jordi Ortuño; Roberta Pacifici; Piergiorgio Zuccaro; Jordi Segura; Rafael de la Torre
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.